Ying has more than 180 primary patents and patent applications which have led to 11 spin-offs. One such spin-off — SmartCells Inc., has a technology that is capable of autoregulating the release of insulin, depending on the blood glucose levels for treating diabetes. The company was acquired by pharmaceutical giant Merck in 2010.[1]